The Pfizer logo. Pfizer's Talzenna-Xtandi combination won an expanded FDA approval on October 26, 2026. Health FDA expands Pfizer's Talzenna-Xtandi approval to earlier prostate cancer Mono Scoops 2d The US Food and Drug Administration expanded approval of Pfizer's Talzenna plus Xtandi combination on October 26 to men with HRR-mutated metastatic prostate cancer that has not yet become resistant to hormone therapy, based on a 52% reduction in progression or death in the TALAPRO-3 trial. Read Full Story
